Sanofi
Latest Sanofi News and Updates
A Look at Sanofi’s Post-2Q17 Valuation
Sanofi (SNY), one of the world’s largest pharmaceutical companies, reported operational growth of 5.5% to reach revenue of 8.7 billion euros in 2Q17.
Pfizer’s Important Product Developments in 2Q17
Pfizer’s (PFE) innovative health business and essential health business are focusing on growth. To strengthen the innovative health business, the company is focusing on the development of new drugs…
Ozanimod Could Drive Celgene’s Long-Term Growth
The Phase 3 RADIANCE trial enrolled 1,313 RMS patients and conducted the trial in 21 countries.
GlaxoSmithKline’s 2Q17 Earnings: Vaccines Business
GSK’s Vaccines business reported 16.0% growth to ~1.1 billion pounds in 2Q17, including 5.0% growth at constant exchange rates and 11.0% positive impact of foreign exchange.
Dupixent Could Substantially Drive Regeneron’s Growth
In March 2017, the FDA approved Regeneron and Sanofi’s Dupixent injection for the treatment of adult individuals with moderate to severe atopic dermatitis.
Eli Lilly in 2Q17: Performance of New Products
For 2Q17, Basaglar sales were $86.6 million. Of that, $60.0 million was from sales in the US markets, while $27.0 million was from international sales.
Unpacking GlaxoSmithKline’s 2Q17 Revenue Expectations
Analysts expect to see a growth of ~11.4% in GlaxoSmithKline’s (GSK) 2Q17 revenues, which are expected to total nearly 7.3 billion British pounds.
Novartis in 2Q17: Performance of Innovative Medicines
The overall contribution of the Innovative Medicines segment was ~67.6% at $8.28 billion for 2Q17.
Novartis’s 2Q17 Estimates: Innovative Medicines Segment
The overall contribution of Novartis’s (NVS) Innovative Medicines segment is ~67.0% of its total revenues.
Analysts Expect Novartis’s Revenues to Fall in 2Q17
Analysts expect Novartis’s (NVS) revenues to fall ~1.6% to $12.3 billion in 2Q17 due to the effects of the acquisition and divestiture of some of its products.
What We Can Expect from Eli Lilly and Company in 2Q17
A look at Eli Lilly and Company Headquartered in Indianapolis, Indiana, Eli Lilly and Company (LLY) is a US pharmaceutical company focused on human pharmaceuticals and animal health. Stock price performance Eli Lilly’s stock price has fallen ~4.4% in 2Q17. However, the stock price had risen 10.9% year-to-date as of July 7, 2017. Analysts’ recommendations Wall […]
Novartis Stock in 2Q17: How Has It Performed?
A look at Novartis Headquartered in Basel, Switzerland, Novartis (NVS) is a pharmaceutical company specializing in the research, development, manufacturing, and marketing of a broad range of healthcare products, mainly pharmaceuticals. The company has segregated its business into three segments: Innovative Medicines, Sandoz (generic), and Alcon (eye care). Stock price performance Novartis’s stock price has […]
What’s in Biogen’s Clinical Pipeline?
Currently, Biogen is conducting 13 clinical studies in early phases and expects promising results from those trials.
Pfizer’s Profitability in 1Q17
Pfizer’s gross margin for 1Q17 was 81.0%, a 0.70% rise compared to 80.3% in 1Q16.
Inside Vertex Pharmaceuticals’ Revenue Trend
In 2016, Vertex Pharmaceuticals (VRTX) reported revenues of around ~$1.7 billion, which reflected a whopping 65% YoY (year-over-year) growth.
Eosinophilic Esophagitis: Major Market Opportunity for Dupixent?
Regeneron (REGN) has obtained positive results from its Phase 2 proof-of-concept study evaluating Dupixent in eosinophilic esophagitis.
Dupixent May Prove Effective in Multiple Diseases
Regeneron plans to discuss Dupixent’s innovative mechanism-based treatment approach with regulatory authorities.
Dupixent May Be a Major Growth Driver for Regeneron in 2017
After Dupixent’s commercial launch, Regeneron has been involved in creating awareness for the drug among physicians who have been treating AD patients.
Why Lupron Could Continue to Generate Steady Revenue
In 2016, AbbVie’s (ABBV) Lupron generated revenue of $821 million, a slight fall of 0.6% year-over-year (or YoY). In 1Q17, Lupron reported revenue of ~$194 million.
What Drove Pfizer in 1Q17?
Growth drivers for Pfizer (PFE) include products contributing to operational growth, such as BMP2, Celebrex, Ibrance, Lyrica, and Xeljanz.
Inside Novartis’s Innovative Medicines Segment in 1Q17
Novartis’s (NVS) Innovative Medicines segment contributed ~67% of NVS’s total revenues in 1Q17.
Inside Novartis’s Segment-Wise Performance in 1Q17
Novartis is largely exposed to currency risk, as ~50% of its total revenues are reported from international markets.
GlaxoSmithKline’s Pharmaceuticals Segment in 1Q17
The Pharmaceuticals segment reported an operational growth of 4.0% and a 13.0% positive impact of foreign exchange, resulting in a rise of 17.0% in revenues.
How AstraZeneca’s Growth Platforms Performed in 1Q17
A few of the segments AstraZeneca identifies as growth platforms include Respiratory products, new Cardiovascular and Metabolic Diseases products, and new Oncology products.
Sanofi’s Generics and Consumer Healthcare Business in 1Q17
Sanofi’s (SNY) Generics business contributes ~5% to the group’s total revenues.
Performance of Sanofi’s Established Prescription Products in 1Q17
Revenues from Sanofi’s Established Prescription Products rose 0.6% at constant exchange rates during 1Q17 and reported revenues of ~2.6 billion euros in 1Q17.
Performance of Sanofi Genzyme in 1Q17
Sanofi (SNY) reported growth of over 15% at constant exchange rates in its 1Q17 revenues from Genzyme.
Gardasil and Merck’s Vaccines Business in 1Q17
Gardasil is Merck’s (MRK) leading vaccine franchise. Total sales for Gardasil in 1Q17 were $532.0 million, a ~41.0% rise over $378.0 million in 1Q16.
Amgen’s Repatha Could Gain Market Share in 2017
In 1Q17, Amgen’s (AMGN) Repatha witnessed quarter-over-quarter growth in sales volume of ~14% and 28% in the US and Europe, respectively.
What Could Drive Amgen’s Growth in 2017?
Enbrel, Neulasta, and Epogen are among Amgen’s (AMGN) major revenue-generating drugs, each with annual sales in excess of $1 billion. Enbrel and Neulasta together accounted for ~46% of Amgen’s 2016 revenues.
Why Zoetis’s Apoquel and Cytopoint Are Expected to Report Robust Revenues
In 1Q17, Zoetis’s (ZTS) dermatology portfolio reported revenues of ~$57 million, driven by the steady adoption of Cytopoint and Apoquel.
Why Zoetis Expects to See Robust Revenue Growth in 2017
Zoetis (ZTS) has adopted a targeted R&D strategy that has resulted in multiple new product launches.
How GlaxoSmithKline’s Vaccines Business Performed in 1Q17
GlaxoSmithKline (GSK) is focused on strengthening its vaccines business, so it acquired the meningitis and other vaccines business from Novartis (NVS).
Performance of Eli Lilly & Co.’s Elanco in 1Q17
Eli Lilly & Co.’s (LLY) Animal Health company, Elanco, reported an increase of 2% in revenues to $769.4 million in 1Q17, compared to $754.6 million in 1Q16.
How GlaxoSmithKline’s Business Segments Performed in 1Q17
The company reported operational growth of 5% in its revenues to 7.4 billion pounds for 1Q17.
Novartis’s 1Q17 Earnings: Innovative Medicines Segment
Novartis’s (NVS) Innovative Medicines segment contributed ~66.6% to overall 1Q17 revenue, or $7.7 billion.
Why Novartis’s 1Q17 Revenues Missed Analysts’ Estimates
Novartis (NVS) released its 1Q17 earnings on April 25, 2017, reporting a 25.0% rise in revenues at constant exchange rates compared to 1Q16.
Dupixent Expected to Be a Solid Addition to Regeneron’s Portfolio
On March 28, 2017, the FDA approved Regeneron (REGN) and Sanofi’s (SNY) Dupixent for the treatment of patients with moderate-to-severe eczema or atopic dermatitis (or AD).
GlaxoSmithKline’s 1Q17 Estimates: Vaccines Business
The Novartis acquisition has improved sales for GSK’s Vaccines business, mainly driven by the sales of meningitis vaccines Bexsero in Europe and Menveo in the US and Europe.
Analyst Ratings and Recommendations for Novartis
As of April 21, 2017, there are five analysts tracking Novartis. Of those, two have recommended a “strong buy,” and one has recommended a “buy.”
Novartis’s 1Q17 Estimates: Innovative Medicines Segment
Novartis’s (NVS) Innovative Medicines segment includes products for therapeutic areas such as oncology, cardiometabolic, immunology, and dermatology.
Analyst Estimates for Novartis’s 1Q17 Earnings
Novartis is set to release its 1Q17 earnings on April 25, 2017. Analysts estimate its 1Q17 EPS at $1.12 with revenues of ~$11.7 billion.
Eli Lilly’s 1Q17 Estimates for Humalog, Other Endocrine Products
Eli Lilly’s (LLY) human pharmaceutical segment contributes ~85.0% to Lilly’s total revenues.
Why Sanofi’s Consumer Healthcare and Generics Segment Still Matters
Sanofi’s (SNY) Consumer Healthcare segment reported a 1.6% YoY (year-over-year) fall in revenues at 3.33 billion euros (about $3.56 billion) in 2016.
Are Sanofi’s Established Prescription Products Adding Up?
Sanofi’s (SNY) Established Prescription Products segment contributed nearly 30.5% of the company’s total revenues in 2016.
Sanofi Genzyme Continued Growth in 2016
Sanofi’s (SNY) 2016 revenues were mainly driven by Sanofi Genzyme and Sanofi Pasteur.
Inside Sanofi’s Overall Revenue Performance in 2016
Sanofi (SNY) reported a YoY (year-over-year) revenue growth of ~1.2% at constant exchange rates for 2016.
Performance of GlaxoSmithKline’s Vaccines Business in 2016
GSK’s Vaccines business reported growth of 14% to ~4.6 billion pounds in 2016.
GlaxoSmithKline’s Pharmaceuticals Segment Performance
Overall, the Pharmaceutical segment’s contribution to GSK’s total revenues was 57.7% in 2016.
Sandoz: Novartis’s Generics Business in 2016
Sandoz, the generics arm of Novartis (NVS), is the number two generic medicines provider worldwide, and it’s number one in differentiated generics.